Loss Per Common Share (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):


	For the Year Ended December 31,
		2023		2022		2021
Loss from continuing operations		$	(113,040)	$	(18,701)	$	(30,284)
Loss from discontinued operations, net of tax		—		(463)		(7,317)
Loss before preferred dividends and accretion of Series A Preferred Stock		(113,040)		(19,164)		(37,601)
Dividends and accretion of Series A Preferred Stock		(29,220)		—		—
Net loss attributable to common shareholders of Evolent Health, Inc.		$	(142,260)	$	(19,164)	$	(37,601)

Weighted-average common shares outstanding - basic and diluted		111,251		93,699		86,067





Loss per common share
Basic and diluted:
Continuing operations		$	(1.28)	$	(0.20)	$	(0.35)
Discontinued operations		—		—		(0.09)
Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.		$	(1.28)	$	(0.20)	$	(0.44)

Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share

Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):


	For the Year Ended December 31,
		2023	2022	2021
Restricted stock units ("RSUs"), performance-based RSUs (“PSUs”) and leveraged stock units ("LSUs")		1,352	1,804	1,807
Stock options		794	1,769	2,036
Series A Preferred Stock		4,375	—	—
Convertible senior notes		6,808	9,574	12,602
Total		13,329	13,147	16,445